SpringerLink
Log in

Adjuvante Therapie des Mammakarzinoms

  • Chapter
  • First Online:
Therapiehandbuch Gynäkologie und Geburtshilfe

  • 5002 Accesses

Zusammenfassung

Damit für die am Mammakarzinom erkrankte Patientin die optimale Therapieentscheidung getroffen werden kann, ist es zunächst wichtig, das Mammakarzinom als systemische Erkrankung zu verstehen. Hierdurch werden auch die Therapieziele (Therapie des lokalen Tumors, Verhinderung von Rezidiv und Fernmetastasen) klar.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (France)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 86.99
Price includes VAT (France)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
EUR 108.44
Price includes VAT (France)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Baselga J, Bradbury I, Eidtmann H (2012) First results of the NeoaLTTO trial (BIG 01-06/EGF 106903): lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoaLTTO): a randomized open label multicenter phase 3 trial. Lancet 379(9816):633–640

    Article  CAS  Google Scholar 

  • Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24(13):2019–2027

    Article  CAS  Google Scholar 

  • Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 30(7):709–717

    Article  CAS  Google Scholar 

  • Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 353(8):793–802. http://www.nejm.org/doi/abs/10.1056/NEJMoa050434

  • Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al (2018) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438. https://doi.org/10.1200/JCO.18.01160

  • Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K et al (2016) Comparison of endopredict and epclin with oncotype dx recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108(11):djw149

    Article  Google Scholar 

  • Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729. http://www.nejm.org/doi/10.1056/NEJMoa1602253

  • Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia. J Clin Oncol 21(8):1431–1439

    Article  CAS  Google Scholar 

  • Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15(9):997–1006

    Article  CAS  Google Scholar 

  • Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446. http://www.nejm.org/doi/10.1056/NEJMoa1412379

  • De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53. http://www.ncbi.nlm.nih.gov/pubmed/18165639

  • Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872. http://www.ncbi.nlm.nih.gov/pubmed/25740286

  • Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al (2018) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2  ×  2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872. https://www.sciencedirect.com/science/article/pii/s0140673614620481 ([Internet] 2015 May 9 [cited 2018 Feb 21])

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

    Article  Google Scholar 

  • EBCTCG (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379(9814):432–444. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273723/

  • Eiermann W, Pienkowski T, Crown J, Chap L, Pawlicki M, Martin M, et al (2009) BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC → T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. Cancer Res 69(2):77. http://cancerres.aacrjournals.org/content/69/2_Supplement/77.abstract

  • Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672–2685

    Article  CAS  Google Scholar 

  • Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32

    Article  CAS  Google Scholar 

  • Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013a) Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206–2223

    Article  CAS  Google Scholar 

  • Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter TM et al (2013b) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028

    Article  CAS  Google Scholar 

  • Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219. http://www.nejm.org/doi/10.1056/NEJMoa1604700

  • Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled phase III trial. J Clin Oncol 31(11):1398–1404. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612593/

  • Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M et al (2016a) West German study group phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341–2349

    Article  Google Scholar 

  • Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH et al (2016b) Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 27(6):1035–1040

    Article  CAS  Google Scholar 

  • Gray R (EBCTCG) et al (2018) Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS GS3-03

    Google Scholar 

  • Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983

    Article  CAS  Google Scholar 

  • Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133–140

    Article  CAS  Google Scholar 

  • L in EBCOG (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369(9574):1711–1723. http://www.sciencedirect.com/science/article/pii/s0140673607607788

  • Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, Mclntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol 27(8):1177–1183

    Article  CAS  Google Scholar 

  • Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 27(34):5685–5692

    Article  CAS  Google Scholar 

  • Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462

    Article  CAS  Google Scholar 

  • Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25(19):2664–2670

    Article  CAS  Google Scholar 

  • Liedtke C, Jackisch C, Thill M, Thomssen C, Müller V, Janni W, AGO Breast Committee (2018) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018. Breast Care 13:196–208. https://doi.org/10.1159/000489329

    Article  PubMed  PubMed Central  Google Scholar 

  • Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL et al (2003) HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21(3):453–457

    Article  CAS  Google Scholar 

  • Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, et al (2010) Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. N Engl J Med 363(23):2200–2210. http://www.nejm.org/doi/abs/10.1056/NEJMoa0910320

  • Moebus V, Jackisch C, Lueck HJ, Du Bois A, Thomssen C, Kurbacher C et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874–2888

    Article  CAS  Google Scholar 

  • Nitz U, Gluz O, Christgen M, Grischke E-M, Augustin D, Kümmel S, et al (2016) Final analysis of WSG-ADAPT HER2+/HR- trial: efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC). J Clin Oncol 34(15):518. http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.518

  • Perez E, Suman V, Davidson N, Gralow J, Kaufman P, Ingle J, et al (2010) Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of Trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 69(24):80. https://cancerres.aacrjournals.org/content/69/24_Supplement/80.short

  • Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V et al (2015) Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 151(2):251–259

    Article  CAS  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672. https://www.nejm.org/doi/full/10.1056/nejmoa052306

  • Rea D, Hasenburg A, Seynaeve C, Jones S, Vannetzel J, Paridaens R, et al (2009) Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Res 69(24):11 LP-11. http://cancerres.aacrjournals.org/content/69/24_Supplement/11.abstract

  • Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8 · 1 years median follow-up. Lancet Oncol 12(12):1101–1108

    Article  CAS  Google Scholar 

  • Romond EH, Perez E, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684

    Article  CAS  Google Scholar 

  • Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18420499

  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al (2015a) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373(21):2005–2014. http://www.nejm.org/doi/10.1056/NEJMoa1510764

  • Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, et al (2015b) Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 33(21):2353–2360. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500829/

  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. http://www.nejm.org/doi/abs/10.1056/NEJM200103153441101

  • Slamon D et al (2009) BCIRG 006 Phase 3 trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in the adjuvant treatment of HER2 – amplified e. Cancer Res Abstr 69(24 Suppl)

    Google Scholar 

  • Spielmann M, Roché H, Delozier T, Canon J-L, Romieu G, Bourgeois H, et al (2009) Trastuzumab for patients with axillary-node – positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134. https://doi.org/10.1200/JCO.2009.23.0946

  • Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can. J Clin Oncol 23(31):7811–7819

    Article  CAS  Google Scholar 

  • Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356

    Article  CAS  Google Scholar 

  • Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747–756

    Article  Google Scholar 

  • von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al (2018) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Frauenklinik, Universitätsklinikum Ulm, Ulm, Deutschland

    Marie Tzschaschel & Jens Huober

Authors
  1. Marie Tzschaschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jens Huober
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marie Tzschaschel .

Editor information

Editors and Affiliations

  1. Fürst-Stirum-Klinik Bruchsal Frauenklinik, Bruchsal, Germany

    Jürgen Wacker

  2. Praxisklinik am Rosengarten, Mannheim, Germany

    Martin Sillem

  3. Praxisklinik am Rosengarten, Mannheim, Germany

    Gunther Bastert

  4. Frauenklinik, Universitätsklinikum Erlangen-Nürnberg Frauenklinik, Erlangen, Germany

    Matthias W. Beckmann

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tzschaschel, M., Huober, J. (2020). Adjuvante Therapie des Mammakarzinoms. In: Wacker, J., Sillem, M., Bastert, G., Beckmann, M. (eds) Therapiehandbuch Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59809-2_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59809-2_31

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59808-5

  • Online ISBN: 978-3-662-59809-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation